ongoing

EPIC STEMI is a randomized, double-blind, placebo controlled parallel group clinical trial evaluating the effects of acute treatment with a PCSK9 inhibitor, alirocumab, versus placebo on low-density lipoprotein (LDL) in 100 high-risk patients presenting with STEMI and referred for primary PCI.

The objective is to determine the effect of acute, rapid lowering of LDL cholesterol with alirocumab added to high dose statin therapy in patients with STEMI undergoing primary PCI.

The hypothesis is that, in patients with STEMI undergoing primary PCI, rapid lowering of LDL cholesterol with a PCSK9 Inhibitor (alirocumab) initiated in the acute setting pre-PCI, will favourably affect LDL cholesterol concentrations compared with placebo.

EPIC STEMI Slides - Download PDF
Study Type

Interventional - Drug

Study Design

A randomized, double-blind, placebo RCT

NO. of Countries

1

NO. of Sites

1

NO. of Participants

100

Study Period

2018-2020

Sponsor

PHRI

Sanofi

Back To Top